Published on September 24, 2013 at 2:10 PM
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that its subsidiary, Cardiome Development AG, has entered into an agreement with LifePharma (Z.A.M) Ltd., to sell and distribute BRINAVESS™ (vernakalant intravenous) exclusively in Cyprus. Under the terms of the agreement, LifePharma has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement were not disclosed.
"We are pleased to enter into this agreement with LifePharma and continue to have BRINAVESS available to our customers in Cyprus," said Karim Lalji, Cardiome's Chief Commercial Officer. "LifePharma is a pharmaceutical industry leader in Cyprus and we are excited to leverage their deep expertise in this market."
"We are pleased to have partnered with Cardiome to commercialize BRINAVESS in Cyprus," said Savvas Jacovides, President of the Board of Directors of LifePharma (Z.A.M) Ltd. "Our customers will be delighted to know that access to BRINAVESS will continue through LifePharma and that we are committed to meeting their needs to have the product available."
SOURCE Cardiome Pharma Corp.